Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. [electronic resource]
Producer: 20150512Description: 1056-63 p. digitalISSN:- 1550-7416
- Adenocarcinoma -- blood
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- blood
- Bayes Theorem
- Bevacizumab
- Biological Availability
- Capecitabine
- Cisplatin -- administration & dosage
- Deoxycytidine -- administration & dosage
- Disease Progression
- Drug Monitoring
- Female
- Fluorouracil -- administration & dosage
- Gastrectomy
- Humans
- Male
- Metabolic Clearance Rate
- Middle Aged
- Models, Biological
- Stomach Neoplasms -- blood
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.